Tempus AI
Tempus AI is a publicly traded precision medicine platform that combines genomic sequencing, multimodal clinical data, and AI to support oncology diagnosis and drug development. It operates exclusively in enterprise B2B channels — healthcare systems, pharma companies, and research institutions — with no SMB or self-serve pricing.
Core clinical utility is strong and published-study-validated, but workflow integration depth is severely limited by the absence of a public API, and ROI accessibility is opaque due to enterprise-only contract pricing with no published tiers.
FDA regulatory momentum and pharma partnerships signal output credibility, but the absence of a public privacy policy, no visible SOC 2 certification, and concerning internal culture signals (potential for data governance gaps under high-turnover conditions) constrain the trust score.
Publicly traded on Nasdaq with $1.5B+ total funding, nine-figure pharma partnership deals, 75–85% YoY revenue growth, and active presence at major oncology conferences place Tempus firmly in the top tier of market credibility signals.
No public API, no documented public SDK, no developer portal, and no identifiable open-source repository mean the infrastructure score is capped near the consumer-tool baseline; enterprise integrations exist but are entirely opaque to external evaluation.
Tempus AI is doing something genuinely difficult: turning the chaos of cancer patient data — genomics, imaging, pathology, clinical notes — into actionable intelligence at the point of care and the drug discovery lab bench. Since going public on Nasdaq in June 2024, it has grown revenue by 75–85% year over year, inked nine-figure deals with AstraZeneca and Gilead, and launched a steady drumbeat of new clinical products. The question isn't whether Tempus is building something important — it clearly is. The question is whether your organization is positioned to extract value from it.
Frequently asked
What is Tempus AI?
Tempus AI is a publicly traded precision medicine platform that combines genomic sequencing, multimodal clinical data, and AI to support oncology diagnosis and drug development. It operates exclusively in enterprise B2B channels — healthcare systems, pharma companies, and research institutions — with no SMB or self-serve pricing.
How much does Tempus AI cost?
Tempus AI uses a enterprise pricing model. See the pricing breakdown above for current plans.
What is Tempus AI best for?
Tempus AI is best suited for healthcare.
What is Tempus AI's StackScore?
Tempus AI scores 63/100 on Instawhat.ai's independent StackScore™ — a solid, competitive option.